Cuicui Han

Cuicui Han

Auto-generated profile, based on publicly available information

Cuicui Han

Navy Special Medical Centre, Second Military Medical University/Naval Medical University, Shanghai, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2025 in Arid Land Research and Management
Verified
Journal Article
Closed access
CHCuicui Han
Cuicui Han
WSWenjuan Sang
Wenjuan Sang
ZZZheng Zhou
Zheng Zhou
LYLuyao Yu
Luyao Yu
WWWenhui Wu
Wenhui Wu
YHYing He
Ying He

5 November 2026 in Current Molecular Medicine
Verified
Journal Article
Closed access
YLYujie Liu
Yujie Liu
BGBingjie Guo
Bingjie Guo
LYLuyao Yu
Luyao Yu
YTYufu Tang
Yufu Tang
CHCuicui Han
Cuicui Han
YHYing He
Ying He
Introduction: Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a complex pathogenesis. This study aims to systematically investigate the mechanism of Salvianolic acid E (SAE) in treating UC by identifying its core molecular targets. Methods: Potential target genes of SAE against UC were screened via differential expression analysis of datasets. Integrated approaches including machine learning algorithms, network pharmacology, molecular docking, immune infiltration analysis, and experimental validation were employed to investigate the binding interactions between SAE and target proteins. Results: A total of 13 potential target genes were identified. Machine learning further refined these to five core genes (SLC23A1, SLC6A14, LCN2, PLA2G2A, and CASP1) as key regulatory factors. Among them, SLC23A1 was significantly downregulated, whereas the other four were significantly upregulated. Molecular docking showed putative interactions between SAE and the target proteins. Immune infiltration analysis revealed strong correlations between the core genes and immune cells such as M2 macrophages, neutrophils, and resting mast cells. Cellular-level validation confirmed the expression patterns of these key genes. Discussion: These five core genes constitute a coordinated pathological axis underlying UC progression, which sequentially involves impaired epithelial barrier function, activated innate immune response, amplified pro-inflammatory lipid signaling, and caspase-1-mediated pyroptosis. The stable binding of SAE to these target proteins supports a multi-target synergistic mechanism: SAE may concurrently correct dysregulated solute transport, suppress pro-inflammatory enzymatic activities, and modulate the colonic immune microenvironment. In particular, the strong associations of core genes with neutrophils, M2 macrophages, and resting mast cells suggest that immunomodulation may serve as a critical potential dimension of SAE’s therapeutic efficacy against UC. Our integrated analytical strategy also provides a replicable paradigm for deciphering the pharmacological mechanisms of multi-target natural compounds. Conclusion: The five candidate regulatory genes and the putative binding of SAE to its key targets provide critical insights into the therapeutic mechanism of SAE in UC, offering novel directions for future UC treatment development.